Sonoma Pharmaceuticals, Inc. announced on March 10, 2025, that it has secured extensive regulatory clearances from the Medicines & Healthcare products Regulatory Agency (MHRA) in the United Kingdom. This includes the registration of its manufacturing facility and five of its products.
The newly registered products in the U.K. include Sonoma's hypochlorous acid-based wound irrigation solution, scar management products, wound hydrogel, and skin exfoliant. These clearances establish a regulatory pathway for commercialization.
This achievement is a critical step for Sonoma to expand its presence in the U.K. market, allowing it to introduce its Microcyn technology-based wound care and dermatology products to a new customer base.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.